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Abstract The ability to characterise cannabinoid
chemical phenotype (chemotype) accurately is impor-
tant for the development of Cannabis sativa L.
cultivars specific for pharmacological, hemp fibre, or
seed end use. Although a number of chemotyping and
genotyping methods have previously been developed
to predict and characterise cannabinoid composition,
only a subset of the gene pool has been examined. A
representative survey from a wide range of geograph-
ically and genetically diverse C. sativa accessions
using liquid chromatography–mass spectrometry
(LC–MS) cannabinoid profiling together with domi-
nant and co-dominant DNA marker assays was
performed. Overall variability of chemotype across
the gene pool was found to be three-fold greater within
heterozygote genotypes than previously reported.
Interestingly, an individual plant of East Asian origin
was found to exhibit a rare propyl alkyl cannabinoid
homologue and a chemotype inconsistent with the
predicted genotype. We propose that in order to carry
out comprehensive screening of genetic resource
collections and to identify chemotypic variants speci-
fic for end-use pharmacological applications, a strat-
egy which adopts both cannabinoid profiling and the
co-dominant DNA marker assay is required. Further
research with consideration of propyl-alkyl-cannabi-
noid homologues should explore the relationship
between chemotype and genotype in greater detail.
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Introduction
Cannabis sativa L. is an erect, diploid, mostly
dieocious (Van Bakel et al. 2011), outcrossing (Fora-
pani et al. 2001) annual herb within the Cannabaceae
family (Small and Cronquist 1976). The species is
characterised by the production of a large range of
biologically active secondary plant metabolites
(ElSohly and Slade 2005; Gertsch et al. 2010; Werz
et al. 2014), with a subset of over 70 terpenophenolic
phytocannabinoid (cannabinoid) compounds (ElSohly
and Slade 2005), some of which appear unique to C.
sativa (Appendino et al. 2011; Gertsch et al. 2010).
Cannabinoids are synthesised in plants in their
carboxylic acid forms (Swift et al. 2013) and accu-
mulate principally within glandular trichomes
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occurring on female inflorescences (Happyana et al.
2013). These form neutral cannabinoids, in a non-
enzymatic thermal conversion reaction (Dussy et al.
2005), with the most notable conversion being that of
delta-9-tetrahydrocannabinolic acid (THCA) to the
psychoactive cannabinoid delta-9-tetrahydrocannabi-
noid (THC).
Cannabinoids have modulating effects on the human
endocannabinoid systemand are believed to be beneficial
in a number of physiopathological processes (Izzo et al.
2009). The pentyl-alkyl-cannabinoids THCA and
cannabidiolic acid (CBDA) are the major constituents
found in plants (De Backer et al. 2009; Swift et al. 2013),
although a series of propyl-alkyl-cannabinoid homo-
logues [delta-9-tetrahydrocannabivarinic acid (THCVA)
and cannabidivarinic acid (CBDVA)] also occur in plants
from specific geographical regions (Baker et al. 1980;
Hillig and Mahlberg 2004). Pentyl-cannabinoids are
formed from cannabigerolic acid (CBGA) (Taura et al.
2007b), while propyl-cannabinoids are formed from
cannabigerovarinic acid (CBGVA) (Shoyama et al.
1984). Oxidocyclization reactions catalysed by THCA
and CBDA synthase (Shoyama et al. 1984), form
THCA ? THCVA (THC(V)A) and CBDA ? CBDVA
(CBD(V)A) respectively (Sirikantaramas et al. 2004;
Taura et al. 2007b) (Fig. 1).
THC(V)A, CBD(V)A and their derivatized forms
exert differing actions on the human endocannabinoid
system and are considered separate pharmacological
entities (Izzo et al. 2009). Three main cannabinoid
chemical phenotypes (chemotypes) are recognised
based on CBD(V)A and THC(V)A composition (De
Meijer et al. 2003); Chemotype I (CBD(V)A:
THC(V)A ratio [1), chemotype II (CBD(V)A:
THC(V)A ratio close to 1:1), and chemotype III
(CBD(V)A: THC(V)A: ratio \1) (De Meijer et al.
1992). Additional chemotypes IV (CBG(V)A:
CBD(V)A/THC(V)A [1) and V (total cannabinoid
content\0.02 %) also occur at low levels within a
subgroup of the C. sativa gene pool (Pacifico et al.
2006).
The ability to characterise cannabinoid composi-
tion is important for the comprehensive screening of
germplasm collections, and is especially relevant in
planning targeted breeding within obligate outcrossing
dioecious species such as C. sativa (Forapani et al.
2001). Accurately characterising chemotypic varia-
tion offers the potential to identify allelic variation that
can contribute to novel cultivars capable of meeting
the demands of quality, safety, and efficacy necessary
for the manufacture of cannabinoid-based pharma-
ceutical-grade botanical extracts (Potter 2014), or
Fig. 1 A single A and B locus genetic model governing
cannabinoid composition in Cannabis sativa L. Adapted from
(De Meijer et al. 2009). Black lines indicate alternative
cannabinoid biosynthetic pathways. Arrows correspond to
associated cannabinoid accumulation and chemotype. The
Apentyl allele is associated with the accumulation of pentyl-
cannabinoid intermediate CBGA, while the Apropyl allele is
associated with the accumulation of propyl-cannabinoid inter-
mediate CBGVA (Shoyama et al. 1984). The BT and BD alleles
encode functional THCA synthase and CBDA synthase
homologs respectively (De Meijer et al. 2003). The BT0 allele
encodes a non-functional THCA synthase homolog, while BDw,
BD01, and BD02 encode non-functional CBDA synthase
homologs (Onofri et al. 2015). The BT allele is associated with
THCA ? THCVA (THC(V)A) and chemotype I (BT) and
chemotype II (BTBD). The BD allele is associated with
CBDA ? CBDVA (CBD(V)A) accumulation and chemotype
III (BD) and chemotype II (BTBD). The BT0, BDw, BD01, and BD02
alleles are associated with CBGA ? CBGVA (CBG(V)A)
accumulation and chemotype IV; cannabidiolic acid (CBDA);
cannabidivarinic acid (CBDVA); cannabigerolic acid (CBGA);
cannabigerovarinic acid (CBGVA); delta-9-tetrahydrocannabi-
nolic acid (THCA); delta-9-tetrahydrocannabivarinic acid
(THCVA)
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indeed for eliminating psychoactive constituents from
industrial hemp (Mandolino and Carboni 2004).
Genetic metabolic engineering through exploitation
of natural occurring allelic and chemotypic diversity
within the gene pool (Barker et al. 2007), and
subsequent generation of novel recombined breeding
lines using marker assisted selection (Mandolino and
Carboni 2004; Potter 2014), may lead to the develop-
ment of standardised multi-targeting botanical drug
products from a single plant line. Rigorous character-
isation of chemotype may also aid in the development
of fibre hemp and seed cultivars which can maintain
levels of THC within legal regulatory thresholds of
0.2 % dry weight (w/w) (DW) (Kojoma et al. 2006;
Mandolino and Carboni 2004; Pacifico et al. 2006).
A number of chemotyping and genotyping methods
have been developed to characterise and predict
cannabinoid composition. Gas chromatography is
commonly used to characterise chemotype and relies
on the thermal conversion of acidic to neutral
cannabinoids, although this reaction can vary between
laboratories and is only partial (Dussy et al. 2005).
Liquid chromatography methods developed more
recently can detect both acidic and neutral cannabi-
noids, therefore providing a more precise character-
isation of chemotype (De Backer et al. 2009). Several
DNA markers associated with the genes encoding
THCA and/or CBDA synthase have been found
beneficial in predicting chemotype during early stages
of plant development (Kojoma et al. 2006; Pacifico
et al. 2006; Rotherham and Harbison 2011; Staginnus
et al. 2014), with the most comprehensively studied in
terms of genetic linkage and sample population
screening being the dominant D589 (Staginnus et al.
2014) and co-dominant B1080/B1192 (Pacifico et al.
2006) DNA sequence characterised amplified region
(SCAR) markers respectively.
To date, the available chemotyping and genotyping
methods have only been applied to a subset of the C.
sativa gene pool (Pacifico et al. 2006; Rotherham and
Harbison 2011; Staginnus et al. 2014). Given the
extensive genetic (Faeti et al. 1996; Gao et al. 2014;
Gilmore et al. 2007; Hillig 2005) and chemotypic
variability (Baker et al. 1980; Hillig and Mahlberg
2004) which appears to exist, use of each approach in
isolation may not be sufficient to account for the full
extent of variation in cannabinoid composition within
the species. In the present study, we carried out a
representative survey from a wide range of
geographically and genetically diverse accessionswith
differing domestication histories. Using a combination
of liquid chromatography–mass spectrometry (LC–
MS) cannabinoid profiling and DNA SCAR markers,
we explored the relationship between chemotype and
genotype in order to develop a comprehensive strategy
for characterising chemotypic diversity in C. sativa.
Materials and methods
Genetic resources
All experimental work, acquisition and storage of the
prohibited plant was performed in accordance with
Sections 23(4)(b) and 41(b) of the NSW Drug Misuse
and Trafficking Act 1985, and under the appropriate
licences issued by the New South Wales Ministry of
Health, Australia. Accessions were sourced from a
global germplasm collection owned by Ecofibre
Industries Operations (EIO) and managed by Southern
Cross University (Table 1). Three genetically diverse
C. sativa groupings were selected (Hillig 2005),
including seven European fibre-type accessions, seven
East Asian fibre-type accessions and eight mixed
origin drug-type accessions.
Growth parameters
Seeds were planted in seedling trays at a depth of 1 cm
in a soil mix comprising of one part vermiculite, one
part peat moss, one part perlite and dolomite (110 g/
100L), and supplemented with CANNA Aqua Vega
nutrient solution. Seeds were grown at temperatures
between 26 and 30 C. 500 mL of water was applied
to13 seedling trays (40 cells of 5.5 9 4 cm) three
times daily for 14 days and were subject to 11 h of
600 w HPS/metal halide light (luminous flux equal to
72,000 lumens) per day. Three female progeny from
each dioecious accession were selected, while three
hermaphrodite plants with mainly female reproductive
tissues from monoecious accessions A (TS1300610),
B (TS1300026), D (TS1300041) and G (TS1300287)
were selected.
Seedlings were transferred into 8 L pots with 1 part
vermiculite, 1 part peatmoss, 1 part perlite soil mix and
dolomite (110 g/100 L). Each 8 L pot contained 100 g
Osmocote Exact nutrient mix and 8 g of Micromax
micronutrient formula. Plants were grown in bespoke
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pollen secure environmentally controlled closed loop
filtered air system growth chambers fitted with ‘smart
valves’ for optimal water regimes. Plants were subject
to 11 h of 600 wHPS/metal halide light (luminous flux
equal to 72,000 lumens) per day and kept at a
temperature between 28 and 32 C to promote flow-
ering. Plants were harvested at maturation, which was
determined when approximately 95 % of the stigma
present on the apical inflorescence were browned and
shrivelled (Staginnus et al. 2014) and before the onset
of seed formation (Pacifico et al. 2006).
DNA marker assays
DNA extraction
Plant leaf material was removed from the apical node
of 14 day-old plants. DNA was extracted using a
DNeasy plant mini kit (Qiagen #69104). Tissue
disruption was completed manually using a pestle and
mortar and ground under liquid nitrogen. Purification
of DNA was determined using the Nanodrop 2000
UV–Vis spectrophotometer (Thermo Scientific). Ratio
of absorbance at 260/280 nm was determined for all
samples, with ratios of 1.7–1.9 and symmetric peaks at
260 nm used to infer optimal DNA purity.
DNA amplification
Amplification of the D589 marker fragment was
achieved using the primers F: 50 CCTGAATTCGA
CAATACAAAATCTTAGATTCAT 30; R: 50 ACT
GAATATAGTAGACTTTGATGGGACAGCAACC
30 (Staginnus et al. 2014). These primers included four
SNPs associated with the functional variant of THCAS
(Kojoma et al. 2006) (BT allele). Each reaction
Table 1 Description of 22 Cannabis sativa L. accessions used to examine the relationship between chemotype and genotype
Accessiona ID Domestication
status




TS1300610 A Cultivar Futura 75 Fibre EF Europe France
TS1300026 B Cultivar USO11 Fibre EF Europe Ukraine
TS1300037 C Cultivar Kompolti Fibre EF Europe Hungary
TS1300041 D Cultivar Futura 77 Fibre EF Europe France
TS1300285 E Cultivar Rastislavicka Fibre EF Europe Slovakia
TS1300289 F Cultivar Krasnodarskaya Fibre EF Europe Russia
TS1300287 G Cultivar Fedrina 74 Fibre EF Europe France
TS1300317 H Landrace – Fibre EAF East Asia China
TS1300592 I Landrace – Fibre EAF East Asia China
TS1300283 J Landrace – Fibre EAF East Asia China
TS1300567 K Cultivar MS-77 Fibre EAF East Asia China
TS1300477 L Landrace – Fibre EAF East Asia China
TS1300594 M Cultivar CHG SSL#12 Fibre EAF East Asia China
TS1300394 N Landrace – Fibre EAF East Asia China
TS1300301 O Cultivar Thai Skunk Drug MOD Mixed Netherlands
TS1300246 P Cultivar Skunk #1 Drug MOD Mixed North America
TS1300248 Q Cultivar Super Skunk Drug MOD Mixed Netherlands
TS1300536 R Landrace – Drug MOD South Asia Nepal
TS1300585 S Landrace – Drug MOD South Asia India
TS1300308 T Landrace – Drug MOD Central-Southern Asia Afghanistan
TS1300493 U Landrace – Drug MOD East Asia China
TS1300609 X Cultivar Pan 3 Drug MOD Mixed Unknown
Accessions sourced from the Ecofibre global Cannabis sativa. L. germplasm collection
EF European fibre, EAF East Asian fibre, MOD mixed origin drug-type
a Accessions were selected from three genetically and chemotypically diverse C. sativa groupings (Hillig 2005; Hillig and Mahlberg
2004)
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contained 1.5 mMMgCl2, 0.2 mM dNTPs, 0.2 lM of
each of the forward and reverse primers, and 2 U
Platinum Taq DNA Polymerase (Life Technologies
#10966-034). Thermocycling parameters used during
PCRwere 96 C for 2 min, then 35 cycles of 94 C for
20 s, 64 C for 30 s, 72 C for 1 min 30 s, followed
by a final extension of 72 C for 5 min.
Amplification of B1080/B1192 marker fragments
was achieved using a primer common to both synthases
F: 50 AAGAAAGTTGGCTTGCAG 30, and a THCAS-
specific primer R: 50 TTAGGACTCGCATGAT-
TAGTTTTTC 30, and a CBDAS-specific primer R: 50
ATCCAGTTTAGATGCTTTTCGT 30 (Pacifico et al.
2006). PCR parameters have not been previously
reported for the co-dominant DNA marker (Onofri
et al. 2015; Pacifico et al. 2006) and these were
optimised as follows: each reaction contained 1.5 mM
MgCl2, 0.2 mMdNTPs, 0.4 lMfor the forward primer
and 0.2 lM for THCAS-specific and CBDAS-specific
reverse primers, and 2 U Platinum Taq DNA
Polymerase (Life Technologies #10966-034). Ther-
mocycling parameters were 94 C for 2 min, then 25
cycles of 94 C for 30 s, 58 C for 30 s, 72 C for
1 min 15 s.
PCR reactions were performed in 0.2 mL 96 well
PCR plates (Thermo Scientific #AB-0600) sealed with
flat cap strips (Thermo Scientific #AB-0786) using a
Gradient Palm–CyclerTM (Corbett Life Science) and
occurred in a total volume of 50 lL. D589 and B1080/
B1192 amplification products were separated by
electrophoresis on a 1.5 and 1 % SeaKem LE
agarose gel (Cambrex #50004) stained with GelRedTM
(Biotium #41003) respectively. Amplification prod-
ucts were then visualized under UV illumination using
the Bio-Rad Molecular Imager Gel DocTM XR?
system using Image LabTM software.
LC–MS cannabinoid profiling
Sample extraction
Bracts, bracteoles and surrounding leaf tissues were
collected from the upper 30 cm of female inflores-
cences [International Union for the Protection of New
Varieties of Plants (UPOV) (www.upov.int)]. Sample
preparation and extraction followed those of De
Backer et al. (2009). Leaf material was dried at 35 C
in a forced ventilation oven for 48 h. Seeds and stalks
were separated and discarded manually and 1 g of
dried leaf material was ground using aMixer Mill MM
301 (Retsch GmbH) at 30 rotations/second for 30 s.
Extractions were performed in duplicate for each
plant. 250 mg of dried ground leaf tissue was weighed
into a 25 mL volumetric flask and extracted by
agitation in 25 mL mixture of methanol/chloroform
(v/v: 9/1) for 30 min. 1 mL of the extract was
evaporated under a gentle stream of nitrogen (N2)
and resuspended in 1 mL of water/methanol (v/v: 5/5).
Samples were sonicated for 30 s and centrifuged using
a Compact centrifuge 2–5 (Sigma) at 3000 rpm for
7 min to remove particulate material. 500 lL of the
supernatant was transferred into 2 mL screw cap glass
amber vial (Agilent Technologies #5182-0716). All
solvents used for extractions and HPLC analysis were
HPLC grade.
LC–MS parameters
LC–MS chromatographic runs were performed using
an Agilent 1290 Infinity analytical HPLC instrument
(Agilent Technologies, Palo Alto, CA, USA) equipped
with a vacuum degasser, binary pump, autoinjector,
and diode array detector (DAD, 1260), coupled with
an Agilent 6120 Quadrupole mass detector (MSD).
The LC–MS system was controlled using Agilent
ChemStation software (Rev. B.04.03). Absorbance
was monitored at 210, 272, 280, 330, and 360 nm. The
column used was an Agilent Eclipse plus rapid
resolution high definition (RRHD) C18 column
(1.8 lm; 50 9 2.1 mm internal diameter). Column
temperature was set at 30 C.
A linear gradient elution program was applied with
the mobile phase containing acetonitrile with 0.005 %
trifluoroacetic acid (TFA) and Milli-Q water with
0.005 % TFA. The solvent gradient was programmed
from 10 to 99 % acetonitrile with 0.005 % TFA in
11.5 min. 99 % acetonitrile with 0.005 % TFA was
maintained for 1.5 min, recalibrated to 10 % in 2 min
and then held at 10 % for a further 1 min. The total run
time was 15 min. Flow rate and injection volume were
set at 0.3 mL/minute and 3 lL respectively.
MSD parameters and settings followed those of a
previously validated method (Liu et al. 2014). The
MSD was operated in atmospheric pressure ioniza-
tion–electrospray mode using the following parame-
ters: scan mass range, 100–1200; fragmentor, 150;
capillary voltage, 3000 V (positive); drying gas flow,
12.0 L/min (N2); vaporizer temperature, 350 C;
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nebuliser pressure, 35 psi; drying gas temperature,
350 C. THCA, CBDA, CBGA, cannabigerol (CBG),
delta 9-tetrahydrocannabivarin (THCV) (Weesp, The
Netherlands), THC, CBD, and cannabinol (CBN)
(Capalaba, Australia) cannabinoid reference standards
were scanned to determine the most abundant and
representative signal. Cannabinoids were quantified
using selected-ion monitoring. Cannabinoids were
allocated to one of four available MSD signal channels
(Online Resource 1).
Linearity and reproducibility
Concentrations of cannabinoids were determined from
the linear regression equation of calibration curves of
individual reference standards. Calibration curves
were obtained from five standard solutions comprising
all eight cannabinoid standards, with standard solution
concentrations at 0.08, 0.4, 2, 10, and 50 lg/mL.
Calibration curves were calculated using unweighted
linear regression analysis and expressed using R2.
Calibration curves for all eight cannabinoids were
linear within the concentration range R2[ 0.99 (On-
line Resource 2). Calibration curves were conducted
every 24 h to allow for changes in response factor.
Sample cannabinoid concentrations[50 lg/mL were
diluted in water/methanol (v/v: 5/5) in a 1:20 dilution
to ensure signals were within calibration range.
To determine the precision of the LC–MS instru-
ment, standard solutions were injected six times.
Relative standard deviation (RSD) for each cannabi-
noid peak area was found to be \2 %. THCtotal
(= THC ? THCA), CBDtotal (=CBD ? CBDA), and
CBGtotal (= CBG ? CBGA) (Swift et al. 2013; Taura
et al. 2007a) between sample replicates were typically
\5 % RSD. One way analysis of variance (ANOVA)
calculated using GenStat 64-bit Release 16.1 (VSN
International 2014) indicated that there was no signif-
icant difference in THCtotal F1, 130 = 0.01, P = 0.936,
CBDtotal F1, 130 = 0.00, P = 0.985, and CBGtotal
F1, 122 = 0.02, P = 0.898 between replicates.
Results
We were able to classify individual plants of each
accession according to their chemotype and DNA
marker genotypes. A combination of the D589 and
B1080/B1192 DNA SCAR marker assays generated a
haplotype for each plant which enabled us unequiv-
ocally to assign haplotype to chemotype. Associations
between chemotype and haplotype were determined
specifically at the plant level, as variation in chemo-
type and haplotype occurred between accessions and
segregated within accessions.
Chemotype
Individual plants from each accession were allocated a
chemotype on the basis of their THCtotal, CBDtotal, and
CBGtotal % DW concentrations (Online Resource 3).
A histogram of log10 THCtotal and CBDtotal ratios of
individual plants (N = 66) shows three discrete dis-
tributions (Fig. 2). Based on these distributions, plants
with a log10 CBDtotal: THCtotal ratio -2.64 to -1.88
were assigned to chemotype I, plants with a log10
CBDtotal: THCtotal ratio between -1.15 and 0.46 were
assigned to chemotype II, while plants with a log10
CBDtotal: THCtotal ratio of 0.95–1.51 were assigned to
chemotype III.
No plants were found to have levels of CBGtotal that
exceeded 10 % of the cannabinoid fraction or with
levels greater than either THCtotal or CBDtotal,
although variability in the accumulation of CBGtotal
was observed across chemotypes (Fig. 3). Therefore,
no plants were classified as chemotype IV. Individual
plants within eight out of 22 accessions had more than
one chemotype. Chemotype I, II, III were evenly
distributed within the sample population. CBN con-
tributed negligibly to chemotype and was either
\LOQ, or at levels no [0.004 % DW (data not
shown).
Five individual plants from the East Asian acces-
sions J (TS1300283) and H (TS1300317) had a
THCV:THC ratio [1. HPLC chromatograms at
272 nm showed two unknown peaks at 7.5 and
9.1 min for all five plants (Table 2). Using UV
maxima data and peak fragment ions determined from
a positive MSD scan, these compounds were tenta-
tively identify as THCVA and CBDVA.
Marker genotypes
Individual plants from each accession were classified
according to their marker genotypes, generating a
haplotype from a combination of the D589 and B1080/
B1192 DNA SCAR marker assays. Plants were scored
separately for each marker (Online Resource 3).
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Conformity between the D589 and B1080/B1192
marker genotypes was observed (Table 3). The D589
marker assay scored plants as either BTpresent or
BTabsent, while the B1080/B1192 marker assay scored
plants as either BTHCAS, BTHCASBCBDAS, or BCBDAS.
All plants with a BTpresent D589 marker genotype had
either a BTHCAS or BCBDAS/THCAS B1080/B1192
marker genotype, while all plants with BTabsent D589
marker genotype were found to have a BCBDAS B1080/
B1192 marker genotype.
Chemotype and marker genotype
The chemotype of 65 out of 66 plants were correctly
predicted by both D589 and B1080/B1192 DNA
SCAR marker assays (Table 3). However, the domi-
nant D589 marker assay was less specific in predicting
chemotype than the co-dominant B1080/B1192 mar-
ker assay, and was unable to differentiate between
chemotype I and II. 45 out of 46 chemotype I and II
plants were correctly predicted by the presence of the
D589 BTpresent marker genotype (sensitivity of
97.8 %), while 20 out of 20 chemotype III plants
were correctly predicted by the absence of the BTabsent
genotype (specificity of 100.00 %). Similar results
were observed with the B1080/B1192 marker assay,
with 27 out of 27 chemotype I and 18 out of 19
chemotype II plants correctly predicted byBTHCAS and
BTHCASBCBDAS marker genotypes respectively, while
20 out of 20 chemotype III plants were correctly
predicted by the BCBDAS marker genotype. As
expected there were highly significant associations
between chemotype I–III and marker genotype, Pear-
son’s v22;66 ¼ 61:63, P\ 0.001 (GenStat 64-bit
Release 16.1).
A higher level of variability in cannabinoid com-
position occurred in chemotype II BTHCASBCBDAS
genotypes compared with chemotype I BTHCAS
Fig. 2 Frequency distribution of CBDtotal: THCtotal DW log10
ratios of individual Cannabis sativa L. plants derived from 22
accessions. Three discrete distributions are associated with
chemotypes I–III (Hillig and Mahlberg 2004). Dotted lines
indicate log10 ratio divisions between chemotype I, II, and III;
cannabidiol (CBD); cannabidiolic acid (CBDA);
CBD ? CBDA (CBDtotal); dry weight (w/w) (DW); delta-9-
tetrahydrocannabinol (THC); delta-9-tetrahydrocannabinolic
acid (THCA); THC ? THCA (THCtotal)
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genotypes and chemotype III BCBDAS (BTabsent) geno-
types (Fig. 4). Chemotype II BTHCASBCBDAS geno-
types ranged from 25.1 % THCtotal (72.4 %
CBDtotal)/total cannabinoid fraction to 86.3 % THCtotal
(13.8 % CBDtotal). In contrast, chemotype I BTHCAS
genotypes and chemotype III BCBDAS (BTabsent)
Fig. 3 Penyl-cannabinoid composition within the cannabinoid
fraction of individual Cannabis sativa L. plants derived from 22
accessions indicating variability both within and between
accessions and chemotypes. Letters indicate accession ID
(Table 1). Numbers correspond to each of three plant individ-
uals per accession. Chemotypes determined from the frequency
distributions of CBD ? CBDA (CBDtotal): THC ? THCA
(THCtotal) log10 ratios of individual C sativa plants; cannabidiol
(CBD); cannabidiolic acid (CBDA); cannabigerol (CBG);
cannabigerolic acid (CBGA); CBG ? CBGA (CBGtotal);
delta-9-tetrahydrocannabinol (THC); delta-9-tetrahydro-
cannabinolic acid (THCA)
Table 2 HPLC–DAD spectrum and MSD fragment ion of acidic cannabinoids
Compound Retention time (min) UV maxima (nm) Fragment ion [M ?1] (m/z) Molecular weight (g/mol)
CBDA 8.2 223, 269, 307 341, 359 358.47
CBDVA 7.5 223, 269, 307 313, 331 330.42
THCA 10.0 222, 271, 306 341, 359 358.47
THCVA 9.1 222, 271, 306 313, 331 330.42
HPLC-DAD high performance liquid chromatography-diode array detector, MSD mass detector, CBDA cannabidiolic acid, CBDVA
cannabidivarinic acid, THCA delta-9-tetrahydrocannabinolic acid, THCVA delta-9-tetrahydrocannabivarinic acid, UV ultraviolet
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genotypes ranged from 91.3 % THCtotal (0.3 %
CBDtotal) to 99.5 % THCtotal (0.5 % CBDtotal) and
6.3 % THCtotal (93.7 % CBDtotal) to10.1 % THCtotal
(89.9 % CBDtotal)/total cannabinoid fraction
respectively.
Cannabinoid homologues
A lack of correspondence between chemotype and
genotype was observed in a single individual, H-3,
from the East Asian accessions H (TS1300317). This
Table 3 D589 and B1080/B1192 DNA SCAR marker genotypes and associated chemotype of individual Cannabis sativa L. plants
derived from 22 accessions
Marker genotype Chemotype I (N = 27) Chemotype II (N = 19) Chemotype III (N = 20)
BTpresent 27 18 0
BTHCAS 27 0 0





Bold indicates the dominant D589 DNA sequence characterised amplified region (SCAR) marker genotype (Rows 2 and 5). Rows 3,
4, and 6 indicate the co-dominant B1080/B1192 DNA SCAR marker genotypes. Columns 2–4 indicate the number of DNA SCAR
marker genotypes which predicted chemotype
a Non-correspondence between DNA SCAR marker genotype and chemotype of plant individual H-3
Fig. 4 CBDtotal: THCtotal compositional variability within and
between Cannabis sativa L. chemotypes and its relationship
with the B1080/B1192 DNA SCAR marker genotype. Black
arrow indicates previous range in CBDtotal: THCtotal composi-
tional variability within chemotype II BTHCASBCBDAS genotype
(Pacifico et al. 2006). Data points correspond to CBDtotal:
THCtotal composition within the total cannabinoid
fraction including CBGtotal. Square, circular, and triangular
data points correspond to chemotype III, II, and I respectively;
sequence characterised amplified region (SCAR); cannabidiol
(CBD); cannabidiolic acid (CBDA); CBD ? CBDA (CBDtotal);
delta-9-tetrahydrocannabinol (THC); delta-9-tetrahydro-
cannabinolic acid (THCA); THC ? THCA (THCtotal)
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individual had BTabsent and BCBDAS genotypes associ-
ated with chemotype III (Table 3), despite exhibiting a
THCtotal: CBDtotal ratio associated with chemotype II
(Fig. 3). CBDVA:THCVA log10 ratios, determined
from THCA and CBDA standards, corresponded to
chemotype in four/five plants which demonstrated a
THCV:THC[1. H-3 was found to have CBDVA at
levels exceeding other cannabinoids, and produced a
CBDVA:THCVA log10 ratio of 1.17 and so was
associated with chemotype III. Pentyl- and propyl-
chemotypes and BTabsent ? BCBDAS haplotype for H-3
were confirmed through duplicated LC–MS sample
replicates, and through repeat DNA extraction and




Previously it was shown that chemotype II BTHCAS-
BCBDAS genotypes exhibited a CBDtotal: THCtotal log10
ratio ranging from 0.36 to 0.01 (Pacifico et al. 2006).
In the present study, chemotype II BTHCASBCBDAS
genotypes exhibited a CBDtotal: THCtotal log10 ratio
ranging from 0.46 to –1.15, a greater than three-fold
increase in variability (Fig. 4). GC analysis of chemo-
type II has typically demonstrated a more narrow
range skewed towards a high CBDtotal to THCtotal ratio
(De Meijer et al. 1992; Hillig and Mahlberg 2004;
Weiblen et al. 2015), although a low CBDtotal to
THCtotal ratio similar to those reported here have been
observed in Southeast Asian landraces (Tipparat et al.
2012). Nevertheless, this is the first time that such a
wide range in chemotype II variability has been
unequivocally assigned to genotype and heterozygos-
ity of THCAS and CBDAS.
In a single (B) locus model, chemotype II individ-
uals are assumed to be heterozygote for the co-
dominant BT (THCAS) and BD (CBDAS) alleles (De
Meijer et al. 2003). These alleles encode functional
sequence variants of THCA and CBDA synthase, and
therefore the efficiency (Pacifico et al. 2006) with
which CBG(V)A is converted to THC(V)A (BT) and
CBD(V)A (BD) (Sirikantaramas et al. 2004; Taura
et al. 2007b) (Fig. 1). All things being equal chemo-
type II individuals would be expected to have a
CBDtotal:THCtotal ratio close to 1:1. Deviation from
this ratio within chemotype II has previously been
proposed to be due either to increased catalytic
efficiency of CBDA synthase over THCA synthase
(Weiblen et al. 2015), or from genetic vs environment
interactions (Potter 2009). Considering that ratios of
chemotype II plants deviated both towards CBDtotal
and THCtotal, and that all plants were grown in
environmentally controlled conditions, it could be
suggested that chemotype II variability is largely
influenced by genetic control.
Chemotype II BTHCASBCBDAS genotype variability
may be generated by the presence of alternative
B locus alleles. Four additional alleles encoding
reduced or non-functional variants of THCAS (BT0)
and CBDAS (BDW; BD01; BD02) have been observed
within chemotype IV (Onofri et al. 2015) (Fig. 1).
Individuals homozygote for these alleles have a
reduced capacity to form THCA/CBDA, resulting in
the accumulation of CBGA. These alleles are associ-
ated with nonsynonymous substitutions (Onofri et al.
2015), some of which are non-specific to the D589 and
B1080/B1192 marker genotypes. It is possible these
and potentially other alleles contribute to chemotype II
variability. If these alleles were present in sufficient
frequency to account for chemotype II variability, one
would expect a high frequency of chemotype IV
throughout the gene pool. However, this is unlikely to
be the case, as the distributions of chemotypes I, II,
and III appear to be sufficient to account for the
variation observed within the gene pool (Fig. 3) (De
Meijer et al. 2003; Hillig and Mahlberg 2004; Pacifico
et al. 2006).
Variability within chemotype II BTHCASBCBDAS
genotypes may be more comprehensively explained
by a multi-locus model. The identification of multiple
sequence variants of THCAS or CBDAS within
individuals (Kojoma et al. 2006; Onofri et al. 2015;
Van Bakel et al. 2011; Weiblen et al. 2015) and
segregation in mapping populations, suggests that at
least two closely linked loci govern THC(V)A and
CBD(V)A composition. Recent evidence indicates
that THCAS and CBDAS are positioned 1.1 cM apart
(Weiblen et al. 2015). The presence of contrasting
functional allelic variants of THCAS and CBDAS
occurring at multiple loci may be a possible explana-
tion as to the range and variability in CBDtotal:
THCtotal ratios occurring within chemotype II, and is
also consistent with the reduced representation of
chemotype IV within the gene pool. Analysis of
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THCAS and CBDAS sequence variants and compara-
tive genomic approaches using next generation
sequencing technologies may help to determine the
genomic organisation of chemotype, and whether
alternative alleles contribute to chemotype II
variability.
Characterisation of chemotype
The large range of CBDtotal: THCtotal ratios observed
within chemotype II BTHCASBCBDAS genotypes would
appear to obscure the distinction between chemotypes.
Chemotypes have previously been classified on the
basis of CBDtotal: THCtotal log10 histogram frequency
distributions (Hillig andMahlberg 2004; Pacifico et al.
2008; Staginnus et al. 2014; Tipparat et al. 2012), with
CBDtotal: THCtotal log10 ratio of 0.0 (Pacifico et al.
2008) and -1.0 being used as an arbitrary division
between chemotype I and II (Hillig and Mahlberg
2004; Tipparat et al. 2012). In the present study
chemotype II BTHCASBCBDAS genotypes were found to
exceed these log10 ratios, albeit the latter log10 ratio of
-1.0 was only exceeded by a single individual I-3
(-1.15). Nevertheless, this highlights a potential
limitation of characterising chemotype exclusively
from cannabinoid profiling, and questions the utility of
this approach in determining genotype.
Characterisation and selection for chemotype I
BTHCAS and chemotype III BCBDAS genotypes may aid
in the compositional-selection of uniform plant lines,
with BTHCAS and BCBDAS genotypes found to vary by
only 8.2 % THCtotal (0.2 % CBDtotal) and 3.2 %
THCtotal (3.8 % CBDtotal) within the cannabinoid
fraction respectively (Fig. 4). Selecting for chemotype
III BCBDAS genotypes may prove especially beneficial
for development of uniform plant lines for hemp fibre,
seed, and pharmacological production, given the
strong association between chemotype III and THC
content\0.2 % DW (Pacifico et al. 2008; 2006), and
growing interest in CBD(V)A and CBD(V) derivatives
as pharmacological entities (De Petrocellis et al. 2011;
Gallily et al. 2015; Hill et al. 2013; Iseger and Bossong
2015). However, additional cannabinoid profiling is
required in order to differentiate cannabinoid homo-
logue compositions and to characterise CBDtotal:-
THCtotal chemotype II variability accurately.
Due to variability within chemotype II the unifor-
mity of botanical drug product CBDtotal: THCtotal
ratios has been achieved by combining cannabinoid
extracts from chemotype I and III plants (Potter 2014).
However, this approach requires the growth of
chemotype I drug-type plants (Swift et al. 2013) and
limits compositional control over other potentially
pharmacologically relevant cannabinoids (Izzo et al.
2009). Identification and recombination of novel
chemotype-determining alleles (Barker et al. 2007)
may facilitate the selection of chemotype variants with
CBD(V)A:THC(V)A-specific ratios. This approach to
genetic metabolic engineering may result in the
development of intermediate chemotypes tailored for
specific pharmaceutical applications.
Propyl- and pentyl-cannabinoid chemotypes
A single individual from the East Asian accessions H
(H-3) was characterised as having a propyl-chemotype
III and pentyl-chemotype II profile, while exhibiting a
chemotype III BCBDASBCBDAS ? BTabsent haplotype.
THCA and CBDA synthase are considered isoforms of
the same enzyme (De Meijer et al. 2003; Taura et al.
2007a), sharing 83.9 % amino acid identity (Taura
et al. 2007b). Residues of THCA in chemotype III are
thought to be due to an imperfect capacity of CBDA
synthase to form CBDA (De Meijer et al. 2003).
Chemotype III individuals have been observed to
deviate transitionally from III to II during early stages
of plant development (Pacifico et al. 2008). THCA
residue formation may have occurred in H-3 during
this period and the remaining CBGVA substrate
catalysed to CBDVA during later developmental
stages. Plants which exhibit propyl-chemotype III
profiles are not frequently distributed among the C.
sativa genepool (Baker et al. 1980; Hillig and
Mahlberg 2004). It is possible that two alleles
encoding CBGA-specific or CBGVA-specific CBDA
synthases exist, although this would fail to explain
why THCtotal and CBDtotal were found at an almost
equal ratio in an individual presumably carrying a
functional variant of CBDAS. Further allelism tests on
progenies segregating for propyl- and pentyl-cannabi-
noids may provide insight into the genetic regulation
of homologue variability.
Conclusions
We carried out a representative survey from a wide
range of genetically diverse accessions to explore the
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relationship between chemotype and genotype, and to
identify a suitable strategy for characterising cannabi-
noid compositional variation. A high level of vari-
ability in CBDtotal: THCtotal ratio was observed within
chemotype II BTHCASBCBDAS genotypes. However,
the genetic regulation underlying this variability
remains uncertain. More detailed exploration of the
relationship between chemotype and genotype using
next generation sequencing technologies offers the
potential of characterising chemotype with greater
accuracy, and may lead to advances in the genetic
metabolic engineering of C. sativa for pharmacolog-
ical development. In the interim, a strategy which
adopts the use of both the B1080/B1192 DNA SCAR
marker genotype and careful cannabinoid profiling
may provide an effective approach for classifying
chemotypic variability within diverse germplasm
collections, and may also contribute to the develop-
ment of cultivars with cannabinoid profiles specific for
end-use applications.
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